|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
1994-2-7
|
|
pubmed:abstractText |
Cyclosporin has been demonstrated to reverse resistance to several antineoplastic agents including cisplatin in vitro. The purpose of this Phase I trial was to study the potential clinical application of cyclosporin modulation of cisplatin and to establish a tolerable dose of cyclosporin when combined with a standard dose of cisplatin of 75 mg/m2.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
73
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
196-9
|
|
pubmed:dateRevised |
2010-3-24
|
|
pubmed:meshHeading |
pubmed-meshheading:8275425-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:8275425-Cisplatin,
pubmed-meshheading:8275425-Creatinine,
pubmed-meshheading:8275425-Cyclosporine,
pubmed-meshheading:8275425-Cystadenocarcinoma, Papillary,
pubmed-meshheading:8275425-Cystadenocarcinoma, Serous,
pubmed-meshheading:8275425-Drug Synergism,
pubmed-meshheading:8275425-Drug Tolerance,
pubmed-meshheading:8275425-Female,
pubmed-meshheading:8275425-Genital Neoplasms, Female,
pubmed-meshheading:8275425-Humans,
pubmed-meshheading:8275425-Kidney,
pubmed-meshheading:8275425-Ovarian Neoplasms,
pubmed-meshheading:8275425-Remission Induction
|
|
pubmed:year |
1994
|
|
pubmed:articleTitle |
Cyclosporin enhancement of cisplatin chemotherapy in patients with refractory gynecologic cancer. A Gynecologic Oncology Group Study.
|
|
pubmed:affiliation |
Division of Gynecologic Oncology, University of California Medical Center at Irvine, California.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Multicenter Study,
Clinical Trial, Phase I
|
